,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['bcsm', 'destiny-breast03', 'breast', 'trastuzumab', 'destiny,breast,03']
an acceptable safety reported at a follow-up analysis of the phase 3 destiny-breast03 study has reinforced use of fam-trastuzumab deruxtecan-nxki for patients with her2-positive unresectable or metastatic #bcsm. #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.